TOP STORIES

• BUSINESS Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
  March 11, 2016

• ORGANIZATION “Huge-Seller” Re-Pricing Eroding Predictability of Japanese System: FPMAJ’s Kamoya
  March 10, 2016

• BUSINESS Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
  March 9, 2016

• BUSINESS Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
  March 8, 2016

• BUSINESS Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
  March 7, 2016

• REGULATORY Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
  March 4, 2016

• REGULATORY FY2016 NHI Pricing Reform to Bring “1 Victory, 1 Defeat, 1 Draw” for Industry: MHLW Official
  March 3, 2016

• BUSINESS Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
  March 2, 2016

• BUSINESS Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
  March 1, 2016

• BUSINESS PCSK9 Inhibitor Repatha Expected to Debut this Spring, with Competing Products to Follow
  February 29, 2016

• BUSINESS Torii to Expand Sales Force to 570 by FY2018; Will Actively Seek Acquisitions, Alliances
  February 26, 2016

• BUSINESS Takeda, ASKA Announce Deal on Ecard Authorized Generic
  February 25, 2016

• REGULATORY Possible Price Slash for Big-Sellers Looms as 2017 Tax Hike Nears; All Eyes on Opdivo
  February 24, 2016

• BUSINESS Zosyn Generics Face Labeling Revisions, Shipment Halts over False-Positive Concerns
  February 23, 2016

• BUSINESS Israel’s Pluristem in Hunt for Japan Partner to Market Placenta-Based Cell Therapies
  February 22, 2016

• BUSINESS Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
  February 19, 2016

• BUSINESS Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
  February 19, 2016

• REGULATORY Next Invitation for Sakigake Pathway Might Not Happen Until FY2017, Designations Likely to Decrease: Official
  February 18, 2016

• TRENDS Multiple Authorized Generics Get Approval towards June Listing as Pharmas See Opportunities
  February 17, 2016

• REGULATORY 22 Firms Win Approvals for Zyprexa Generics for June Listing; Kipres AGs Also OK’ed
  February 16, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 170
• 171
• 172
• 173
• 174
• 175
• 176
• 177
• 178
• …
• Next ›
• 最終 »